Topics
May/June 2017 | Cover Focus: A Better Tomorrow
Introduction
Karen Roman, Editor-in-Chief
June 23, 2026
Oculgen Announces First US Patient Enrolled in STAT Trial of OCUL101 for Wet AMD
June 22, 2026
Atsena Doses First Patient in Phase 3 LIGHTHOUSE Trial of Gene Therapy for XLRS
June 19, 2026
Lexitas Pharma Services Named Octane Preferred Advisor
Potential Drug Signals Linked to Wet AMD Identified in Integrative Analysis
May/June 2026 Insert
Editorially Independent Content, Supported With Advertising From Astellas
Supported by Zeiss
Editorially independent supported by Abbvie and Regenxbio
May/June 2026 Supplement
Free Print Subscription
Email Newsletter
Conference Calendar
